Saturna Capital’s Denali Therapeutics DNLI Stock Holding History

Saturna Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,000	Closed	-$223K	–	173
2021 Q4	$223K	Hold	5,000	–	–	﹤0.01%	164
2021 Q3	$252K	Hold	5,000	–	–	0.01%	160
2021 Q2	$392K	Hold	5,000	–	–	0.01%	142
2021 Q1	$286K	Sell	5,000 -2,000	-29%	-$134K	0.01%	148
2020 Q4	$586K	Hold	7,000	–	–	0.01%	126
2020 Q3	$251K	Buy	+7,000	New	+$211K	0.01%	151

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Saturna Capital's DNLI Position: Q1 2022 in Review

Saturna Capital sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 5,000 shares — an estimated $223K sold.

Saturna Capital first reported a position in DNLI in Q3 2020 and held it in 6 quarters. The position peaked at $586K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Saturna Capital reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Saturna Capital sold 5,000 Denali Therapeutics shares in Q1 2022, an estimated $223K.
Saturna Capital first reported a position in Denali Therapeutics in Q3 2020 and held it in 6 quarters.
Saturna Capital's Denali Therapeutics position peaked at $586K in Q4 2020.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Saturna Capital's 13F filing for Q1 2022, filed 10 May 2022.